215results about "Microcarriers" patented technology

The invention discloses a preparation method and application of a cell culture liver based on a microcarrier. The method comprises the steps of obtaining liver seed cells, preparing the microcarrier, culturing cells in vitro based on the microcarrier, preparing the cell culture liver and the like. The preparation method of the cell culture liver based on the microcarrier is provided for the first time, and the preparation scheme that a cell-microcarrier compound serves as a structural unit and is assembled into the cell culture liver after being mixed with an edible material is adopted, so that on one hand, simulation of a real liver lobule structure can be achieved, and on the other hand, simulation of the liver lobule structure can be achieved; the whole structure relation of liver lobules and connective tissues in liver tissues can be simulated, full reduction of animal liver appearance and structural characteristics is achieved, edible materials used in the preparation process are low in price and good in biocompatibility, and the preparation method is suitable for large-scale industrial production. Liver seed cells can be subjected to efficient amplification and albumin synthesis through three-dimensional culture on a microcarrier prepared on the basis of edible materials, so that the cell culture liver is close to a real animal liver in the aspect of nutrition.

The invention discloses a multi-brain organ electron complex as well as a construction method and application thereof. The multi-brain organ electronic complex comprises a microelectrode array and a fusion organ attached to the surface of a chip electrode of the microelectrode array through a PDMS film, and the fusion organ can grow for more than or equal to 120 days through culture. The PDMS film is attached to the surface of the MEA chip electrode, so that the stability of combination of the MEA chip electrode and the organoid is remarkably enhanced, the construction efficiency of a multi-brain organoid electron complex is improved, and the continuity of neural signal detection is improved; a high-performance model platform is provided for multi-brain organ research, and the method has a wide application prospect.

The invention discloses a preparation method of a mesenchymal stem cell exosome based on microcarrier three-dimensional culture and application of the mesenchymal stem cell exosome in anti-aging skin care products. According to the method, a three-dimensional culture system of mesenchymal stem cells is optimized, and the anti-aging function activity of the subsequently separated and purified exosome is remarkably improved by adopting a microcarrier with recombinant collagen as a main component; subsequently, by optimizing an exosome separation and purification technology, and through a specific separation and purification mode and conditions, the exosome with anti-aging active ingredients is further obtained. Experiments prove that the exosome obtained by the method disclosed by the invention can effectively remove metalloproteinase 1 and promote collagen regeneration, has a remarkable anti-aging effect, is suitable for essence, face cream and other dosage forms, and has a wide market prospect.

To provide non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of making and using the same.SOLUTION: The present application provides non-naturally occurring 3D brown adipose-derived stem cell (BADSC) aggregates, methods of making the 3D BADSC aggregates, and methods of using the 3D BADSC aggregates. Also provided herein is an encapsulation system comprising non-naturally occurring 3D brown adipose-derived stem cell aggregates. The 3D brown adipose-derived stem cell aggregate may comprise brown adipose-derived stem cells that express one or more brown adipocyte gene in the absence of differentiation medium.SELECTED DRAWING: None

The invention discloses a natural product-induced artificial nano-vesicle derived from human umbilical cord mesenchymal stem cells and application of the natural product-induced artificial nano-vesicle in ischemic diseases. The preparation method of the nano vesicle derived from the human umbilical cord mesenchymal stem cells comprises the following steps: S1, inoculating the human umbilical cord mesenchymal stem cells to a 3D microcarrier; then adding traditional Chinese medicine active ingredients to activate the human umbilical cord mesenchymal stem cells, continuing to culture, cracking the microcarrier, and harvesting cells; s2, dispersing the human umbilical cord mesenchymal stem cells obtained in S1 to obtain a suspension, extruding the suspension through a polycarbonate film, and then discarding large particles by adopting a gradient centrifugation method to obtain the nano-vesicles. Compared with naturally secreted exosomes, the exosome has the advantages that the yield is increased, the treatment efficiency is improved, the production cost is reduced, and compared with stem cells, the problems of low transplantation rate and the like are avoided. The stem cells are pretreated based on the traditional Chinese medicine, the vesicles are extracted by utilizing an extrusion method, and the yield and the treatment efficiency of the nano vesicles are remarkably improved.

The invention discloses application of a 3D hypoxia mesenchymal stem cell derived exosome preparation in preparation of an immune cell proliferation inhibitor or a medicine for treating acute myocardial infarction, belongs to the technical field of biology, and solves the problems of low cell survival rate and immunological rejection in application of a cell treatment method in the prior art. The 3D hypoxia mesenchymal stem cell derived exosome is used as a medium for treating acute myocardial infarction, and the problem of immunological rejection can be solved.

Sub-millimeter scale three-dimensional (3D) structures are disclosed with customizable chemical properties and / or functionality. The 3D structures are referred to as drop-carrier particles. The drop-carrier particles allow the selective association of one solution (i.e., a dispersed phased) with an interior portion of each of the drop-carrier particles, while a second non-miscible solution (i.e., a continuous phase) associates with an exterior portion of each of the drop-carrier particles due to the specific chemical and / or physical properties of the interior and exterior regions of the drop-carrier particles. The combined drop-carrier particle with the dispersed phase contained therein is referred to as a particle-drop. The selective association results in compartmentalization of the dispersed phase solution into sub-microliter-sized volumes contained in the drop-carrier particles. The compartmentalized volumes can be used for single-molecule assays as well as single-cell, and other single-entity assays.

The embodiment of the invention discloses a method for constructing a cartilage micro-tissue by compounding an extracellular matrix with a vascular matrix component and application. The method comprises the following steps: preparing a porcine decellularized cartilage extracellular matrix; generating a cartilage extracellular matrix suspension; carrying out screening treatment on the cartilage extracellular matrix suspension; preparing a porcine acellular cartilage extracellular matrix microcarrier; preparing a target suspension of a common system from the porcine acellular cartilage extracellular matrix microcarrier and vascular matrix component cells, and transferring the target suspension to a bionic floating microenvironment of a shaker bioreactor for dynamic culture; carrying out culture treatment on the porcine acellular cartilage extracellular matrix microcarrier; and taking out the cell-loaded porcine decellularized cartilage extracellular matrix microcarrier from the cultured and treated porcine decellularized cartilage extracellular matrix microcarrier as the constructed cartilage micro-tissue. According to the embodiment, the condition of secondary injury to a user can be improved and reduced, the repairing effect is improved, and the adaptability of the constructed cartilage micro-tissue is improved.

Provided are methods of obtaining large scale cultures of muscle-derived muscle precursor cells (MPCs) using microcarriers as growth matrices, methods for obtaining therapeutically effective amounts of these cells, populations of cells obtained by the methods, and compositions comprising expanded cells, and a method for preparing a medicament, for example for the treatment of skeletal muscle dysfunction.

Sub-millimeter scale three-dimensional (3D) structures are disclosed with customizable chemical properties and / or functionality. The 3D structures are referred to as drop-carrier particles. The drop-carrier particles allow the selective association of one solution (i.e., a dispersed phased) with an interior portion of each of the drop-carrier particles, while a second non-miscible solution (i.e., a continuous phase) associates with an exterior portion of each of the drop-carrier particles due to the specific chemical and / or physical properties of the interior and exterior regions of the drop-carrier particles. The combined drop-carrier particle with the dispersed phase contained therein is referred to as a particle-drop. The selective association results in compartmentalization of the dispersed phase solution into sub-microliter-sized volumes contained in the drop-carrier particles. The compartmentalized volumes can be used for single-molecule assays as well as single-cell, and other single-entity assays.

The invention relates to a preparation method of a Vero cell influenza virus vaccine, and belongs to the technical field of virus culture. In the culture of the influenza virus, red algae protein and soybean protein hydrolysate are added into a culture medium at the same time, the red algae protein and soybean protein hydrolysate are subjected to low-temperature ammonium sulfate precipitation and PD-10 desalination column purification, natural conformation is kept, integrin-FAK-Src and IGF-1R signal channels can be activated, and cell adhesion and proliferation are promoted; the latter contains soybean protein isolate, polysaccharide and RGD motif peptide, and can form an adhesion film on a substrate and mediate adhesion through integrin. According to the invention, the Vero cells and the recombinant plasmid are combined to improve cell adherence, metabolic homeostasis and oxidation resistance, so that the Vero cells grow at high density and efficiently replicate influenza viruses under a serum-free condition, the virus titer (TCID50) reaches 8.5 log10 / mL, and the Vero cells and the recombinant plasmid are suitable for industrial vaccine production.

The invention discloses a preparation method of a micron-sized cell-matrix co-polymer biological material. The preparation method comprises the following steps: firstly, inducing SHED cells in an ultra-low adsorption plate by using an alpha-MEM culture medium containing serum, GlutaMAXI, vitamin C and the like to form micron-sized spheres (SHED spheres); secondly, taking human dentin, and carrying out mechanical crushing, EDTA (Ethylene Diamine Tetraacetic Acid) demineralization, grinding and sterilization to prepare 1-100 microns of dentin matrix particles (DDMPs); and finally, by taking the GelMA hydrogel as a carrier, entrapping SHED spphere and DDMPs, and carrying out 405nm photo-crosslinking for 30 seconds to form the hydrogel. The co-polymer can significantly promote angiogenesis and osteogenesis coupling regeneration in a bone defect model, and is suitable for oral cavity and cranio-maxillofacial bone repair.

A cell culture microcarrier bead is proposed. The microcarrier bead comprises a bead body having its surface flecked with plasmonic nanoparticles. In a second aspect, the invention relates to a cell culture reactor, containing a cell culture medium and the proposed microcarrier beads. A third aspect of the invention concerns a method for observing living cells on such microcarrier beads. Yet a further aspect of the invention relates to a method for packing nanoparticles on a carrier body.

According to the present invention, the present invention relates to a polymer microparticle having a core-shell structure, which comprises: a core comprising a first biocompatible polymer, a metal ion, and an organic crosslinker having one or more reactive functional groups; and a shell surrounding all or a part of the core and comprising a second biocompatible polymer, a metal ion, and an organic crosslinker having one or more reactive functional groups; and a cell attachment-inducing layer formed on the surface of the polymer microparticle; and a microcarrier, a cell complex comprising the same, a medical composition, a cosmetic composition, a medical product, and a cosmetic product.

The invention relates to a polylactic acid microcarrier and a method for cell amplification by using the polylactic acid microcarrier. The preparation method disclosed by the invention is simple and convenient to operate, the prepared polylactic acid microcarrier is uniform in particle size and pore size distribution, the microcarrier is subjected to surface retreatment, more active sites are provided for cell adhesion, a three-dimensional matrix environment closer to a body is provided, cell amplification is facilitated, the dryness and differentiation potential of stem cells are maintained, and the preparation method is suitable for large-scale popularization and application. And the microcarrier can be repeatedly used, so that the use cost is reduced.

The invention relates to a three-dimensional cellular microcompartment or an assembly of three-dimensional cellular microcompartments of ovoid, cylindrical, spheroidal or spherical shape or substantially ovoid, cylindrical, spheroidal or spherical shape, the smallest dimension of which is between 200 and 400 μm, comprising an external hydrogel layer defining an internal part, said internal part having a granzyme B content of less than 1 μg / ml of medium and comprising between 500 and 5000 lymphocytes forming a three-dimensionally grouped culture. The invention also relates to a method for producing such a microcompartment or microcompartment assembly.

Provided herein are methods for culturing animal cells in a culture medium comprising a culture ingredient that is composed of or produced by yeast. In particular, the culture ingredient comprises, co

A method of generating cells of the T cell lineage is provided that involves culturing a sample comprising stem cells or progenitor cells with an engineered Notch ligand conjugated to a suspension support and isolating cells of the T cell lineage. In one embodiment, the cells of the T-cell lineage are progenitor T cells or mature T cells. Compositions, kits and uses thereof are also provided.

The invention provides a method of culturing adherent cells in a culture vessel using microcarriers coated with a polymer that exhibits a lower critical solution temperature, the method comprising the following steps (1) to (4): (1) a step of culturing the cells on the surfaces of the microcarriers in a culture solution at a temperature at or above the lower critical solution temperature, (2) following step (1), a step of cooling the culture solution to a temperature at or below the lower critical solution temperature, (3) following step (2), a step of stirring the culture solution in the culture vessel to detach the cells from the surfaces of the microcarriers, and (4) following step (3), a step of recovering the cells detached from the surfaces of the microcarriers, as well as temperature-responsive beads composed of a carrier and a polymer coat layer comprising a temperature-responsive polymer having a lower critical solution temperature of 0°C to 50°C, the carrier surface being positively charged and the thickness of the layer of the temperature-responsive polymer being 10 nm to 1000 nm.

The present invention relates to methods for extracting stem cells from a tissue, and culturing, expanding and / or recovering these stem cells, with at most one step of exposure to a protease. The present invention also relates to stem cells obtained by these methods, and compositions comprising thereof, and their applications.

The present invention relates to a method for reducing aggregation in a cell cluster-based cell culture system, such as a microcarrier-based or a spheroid-based cell culture system.

The invention discloses a microcarrier with the surface modified with a herpes virus receptor and application of the microcarrier, and relates to the technical field of animal virology technologies and veterinary biological products. The microcarrier is composed of a microcarrier matrix and herpes virus specific receptor protein fixed to the surface of the microcarrier matrix through chemical coupling; the microcarrier matrix is made of a biocompatible material, and the particle size of the microcarrier matrix is 1-10 [mu] m; the herpes virus specific receptor protein is an extracellular region fragment of a nectin-1 receptor. The method has the advantages that the virus infection efficiency and the virus yield are remarkably improved by accurately regulating and controlling the particle size of the microcarrier and adopting a receptor fixing technology, and the performance is particularly excellent under the condition of low infection complex number; meanwhile, the process is greatly simplified, and the pollution risk is reduced; and the method can be widely applied to herpes virus production, vaccine preparation and difficult-to-culture virus amplification by replacing receptors, and has a wide application prospect.

The present invention relates to a method for the preparation of an assembly of cells and microrobots comprising (a) preparing a suspension of cells and microrobots, wherein the microrobots comprises an alginate, collagen, fibrin, hyaluronic acid / collagen, polyacrylamide, or polyethylene glycol hydrogel capsule, wherein the alginate is conjugated to cell adhesive peptides, and (b) incubating the suspension of (a) to allow the microrobots to form an assembly with the cells via the binding of the cell adhesive peptides to the cells, wherein step (b) and preferably steps (a) and (b) are performed in a conic microcentrifuge tube with a rounded bottom without corners and edges.

The present disclosure provides processes for genetically engineering T cells, such as primary CD4+ T cells and / or CD8+ T cells, for use in cell therapy that does not involve expanding the cells. In particular aspects, the provided processes successfully generate compositions of engineered T cells, such as containing populations of engineered T cells, that express a chimeric antigen receptor (CAR) within a shortened amount of time as compared to alternative engineering processes, such as processes that involve expanding the cells. In certain aspects, the provided processes successfully generate a composition of engineered T cells suitable for use in cell therapy within 4 days from when the process to stimulate or activate the cells is initiated. In some aspects, the resulting engineered cell compositions are composed of cell population that are less differentiated, less exhausted, and more potent than engineered T cell compositions generated by other means, such as by processes that involve expanding the cells. Also provided are compositions of T cells generated by the provided methods and their uses for treating subjects.

The application discloses an engineered umbilical cord stem cell and application thereof in preparation of anti-aging drugs and medical beauty products. The application constructs an engineered cell system with high anti-aging function by designing a fusion polypeptide TAT-SIRT1-SOD (SEQ ID NO: 1) and an anti-p16INK4a monoclonal antibody (mAb-p16) to cooperatively modify the umbilical cord stem cell, and combining a 3D dynamic culture technology. The fusion polypeptide is mediated to cross the membrane by a TAT cell-penetrating peptide, activates SIRT1 and removes mitochondrial ROS; the mAb-p16 is specifically combined with p16INK4a on the surface of a senescent cell, and removes the senescent cell through an ADCC effect. Experiments show that the engineered umbilical cord stem cell can increase the removal rate of the senescent cell by 86.1%, increase the SOD activity by 300%, significantly inhibit the secretion of an inflammatory factor IL-6, and increase the skin collagen density by 148% and reduce the wrinkle depth by 67% in an animal model. The application provides a novel and efficient technical scheme for anti-aging drugs and medical beauty products.

The present invention addresses the problem of providing: a porous support which can be obtained by separating extracellular vesicles with high purity according to size and affinity; and a method for obtaining extracellular vesicles using the porous support. A method for producing an extracellular vesicle using the porous support; and a kit for obtaining an extracellular vesicle comprising the porous support. According to the present invention, provided are a porous support, a method for obtaining extracellular vesicles using the porous support, a method for producing extracellular vesicles using the porous support, and a kit for obtaining extracellular vesicles, the porous carrier is a porous carrier which is combined with a substance having affinity for the extracellular vesicles and has an exclusion limit molecular weight of 800-60000kDa, and the porous carrier is used for obtaining the extracellular vesicles.

The present invention provides a biomaterial for immunomodulation comprising aggregates of phenotypically stabilized cells. Said biomaterial is meant to be preferentially administered in a limited location and provides immunomodulation for preventive or therapeutic purposes.It is also part of the present invention the process for production of the mentioned biomaterial and uses thereof. More specifically, the biomaterial for immunomodulation herein disclosed adds benefit in contexts of transplantation, chronic inflammation, autoimmune diseases, acute inflammation, cancer treatment, or in injured tissue regeneration.

Provided herein are methods for culturing animal cells in a culture medium comprising a culture ingredient that is composed of or produced by yeast. In particular, the culture ingredient comprises, consists essentially of or, or consists of, inactivated yeast. Also provided herein is use of inactivated yeast as a matrix, support, carrier or microcarrier for growing meat cells in in vitro culture.

The present disclosure relates to a stem cell-drug carrier including a melatonin-containing drug carrier and a stem cell, and more particularly, to a use of the stem cell for the treatment of intestinal epithelial damage disease and inflammatory bowel disease. According to the present disclosure, it was confirmed that the stem cell-drug carrier continuously released PGE2 and had excellent revival stem cell induction ability. This means that the stem cell-drug carrier of the present disclosure has an excellent intestinal epithelium regeneration effect, and the stem cell-drug carrier of the present disclosure can be used in various fields of treatment of intestinal damage disease and inflammatory bowel disease.